Typical Wegovy weight loss: what the evidence actually shows

What the STEP 1 trial actually measured

The STEP 1 trial enrolled 1,961 adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, none of whom had type 2 diabetes. Over 68 weeks, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared with 2.4% on placebo. Those are averages, though, and the distribution matters: around 86% of participants on semaglutide lost at least 5%, and roughly a third lost 20% or more. That spread is worth understanding before anyone sets an expectation from a single number.

The trial also measured waist circumference, blood pressure and cholesterol markers, all of which improved alongside weight. Semaglutide works by activating GLP-1 receptors, slowing gastric emptying and signalling fullness to the brain, so the appetite reduction that drives weight loss also tends to shift eating patterns rather than just calorie counts. For a thorough overview of how semaglutide supports weight loss and what it is licensed for, our semaglutide page covers the mechanism in more detail.

The NICE appraisal of semaglutide for weight management (TA875) drew on this and related STEP data when recommending it for adults meeting specific BMI and comorbidity thresholds. NICE's published appraisal sets out those criteria clearly if you want to read the committee's reasoning.

Does typical Wegovy weight loss change at the new 7.2 mg dose?

The short answer is yes, meaningfully. The MHRA approved the higher 7.2 mg maintenance dose of semaglutide in January 2026, and on 14 April 2026 approved a dedicated single-dose 7.2 mg pen for adults with a BMI of 30 or above. Trial data at that dose showed average weight loss of around 20.7% over 72 weeks, which is substantially more than the 2.4 mg maintenance data and closes a gap that previously made tirzepatide look categorically superior on this measure.

The titration pathway remains the same regardless of which maintenance dose someone ultimately reaches: treatment starts at 0.25 mg and increases roughly every four weeks under prescriber review. What changes is the ceiling. Someone who tolerates the medicine well and continues to lose weight on 2.4 mg may be assessed for progression to 7.2 mg; that decision sits with the prescriber, not with the patient. If you're exploring the broader question of how Wegovy works as a weight loss medicine and how it compares with other licensed options, our weight-loss treatment guide sets out the choices available through a regulated UK pharmacy.

One practical note: whether a specific dose or pen format is in stock at any given time is confirmed at the point of consultation. Availability can vary, and a prescriber reviewing your case is the right person to factor that in alongside your dose history.

Why individual results differ so much from the average

A question our prescribers hear most weeks is some version of: "I've been on Wegovy for two months and I've lost less than my friend lost — is something wrong?" Usually, nothing is. Several things shift where any individual sits on the distribution. Starting BMI matters: someone beginning at a BMI of 42 tends to lose more absolute kilograms than someone at 28, even if the percentage is similar. The dose reached matters too, since people who tolerate dose increases fully tend to reach greater total reductions.

Lifestyle changes alongside treatment also contribute. The STEP 1 trial participants all received counselling on diet and activity, which is part of why the licence specifies Wegovy is used alongside a reduced-calorie diet and increased physical activity. Genetics, gut microbiome, baseline metabolic rate and other factors that are not under conscious control also play a role. Weight is not purely a willpower story; the biology is genuinely complex. The full Wegovy weight-loss page goes into this further, including what to discuss with a prescriber if progress stalls.

For anyone tracking their own trajectory, the NHS patient-information page for semaglutide gives practical context on what changes to look for and when to contact a healthcare professional.

When Wegovy is suitable and how to get a clinical assessment

Wegovy's licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not confirm suitability; a prescriber reviews the full clinical picture, including any contraindications and current medicines.

Through regulated private pathways, there is no waiting list and no GP referral required. The process at a GPhC-registered pharmacy involves a free consultation, clinical review the same day by a qualified independent prescriber, and same-day dispatch if treatment is approved. Ongoing clinical review before every repeat order is part of what makes the private route genuinely supervised rather than transactional. If you would like to understand more about how weight changes on Wegovy over a full treatment course, or want to look into the timeline of typical weight loss week by week, those pages go into the finer detail.

The right starting point, if this medicine sounds appropriate for you, is a clinical conversation. Speak to our prescribers to find out whether you are a suitable candidate and what realistic progress might look like in your situation.